AVIR insider filings
Atea Pharmaceuticals, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-19. Screen AVIR transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 3 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 6 legs across 3 filings by 2 insiders — 79,336 shares, $319,804 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 10.
- Largest priced transaction: sale of 22,619 shares @ $3.94 ($89,221) by Lucidi Bruno, filed 2026-11-19.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Polsky Bruce — Director | 2 | — | 4 legs · 49,976 sh · $203,393 | 6 |
| Lucidi Bruno — Director | 1 | — | 2 legs · 29,360 sh · $116,410 | 4 |
Recent insider filings — Atea Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-19 | 4 | Polsky Bruce — Director | Sale (S): 8,750 @ $4.03 | EDGAR |
| 2026-11-19 | 4 | Lucidi Bruno — Director | Option exercise (M): 21,628 @ $1.24 · Sale (S): 6,741 @ $4.03 · Option exercise (M): 53,372 @ $1.24 · Sale (S): 22,619 @ $3.94 · Option exercise (M): 21,628 (derivative) @ $0 · Option exercise (M): 53,372 (derivative) @ $0 | EDGAR |
| 2026-11-18 | 4 | Polsky Bruce — Director | Option exercise (M): 48,028 @ $1.24 · Sale (S): 14,254 @ $4.27 · Option exercise (M): 8,720 @ $1.24 · Sale (S): 8,720 @ $4.03 · Option exercise (M): 18,252 @ $1.24 · Sale (S): 18,252 @ $3.95 · +3 more | EDGAR |
| 2026-06-23 | 4 | Lucidi Bruno — Director | Option exercise (M): 29,600 @ $0 · Option exercise (M): 29,600 (derivative) @ $0 · Grant/award (A): 26,700 (derivative) @ $0 · Grant/award (A): 37,700 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Berman Howard — Director | Grant/award (A): 26,700 (derivative) @ $0 · Grant/award (A): 37,700 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Adams Jerome M. — Director | Option exercise (M): 29,600 @ $0 · Option exercise (M): 29,600 (derivative) @ $0 · Grant/award (A): 26,700 (derivative) @ $0 · Grant/award (A): 37,700 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Murphy Polly A. — Director | Option exercise (M): 29,600 @ $0 · Option exercise (M): 29,600 (derivative) @ $0 · Grant/award (A): 26,700 (derivative) @ $0 · Grant/award (A): 37,700 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Polsky Bruce — Director | Option exercise (M): 29,600 @ $0 · Option exercise (M): 29,600 (derivative) @ $0 · Grant/award (A): 26,700 (derivative) @ $0 · Grant/award (A): 37,700 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | DUNCAN BARBARA GAYLE — Director | Option exercise (M): 29,600 @ $0 · Option exercise (M): 29,600 (derivative) @ $0 · Grant/award (A): 26,700 (derivative) @ $0 · Grant/award (A): 37,700 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | KIRSCH ARTHUR S — Director | Grant/award (A): 26,700 (derivative) @ $0 · Grant/award (A): 37,700 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | BERGER FRANKLIN M — Director | Option exercise (M): 29,600 @ $0 · Option exercise (M): 29,600 (derivative) @ $0 · Grant/award (A): 26,700 (derivative) @ $0 · Grant/award (A): 37,700 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4/A | Murphy Polly A. — Director | Purchase (P): 6,100 @ $4.17 | EDGAR |
| 2026-05-20 | 4 | Murphy Polly A. — Director | Purchase (P): 6,100 @ $4.17 | EDGAR |
| 2026-03-13 | 4 | Corcoran Andrea — See Remarks | Option exercise (M): 60,000 @ $1.24 · Option exercise (M): 60,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Horga Maria Arantxa — Chief Medical Officer | Option exercise (M): 51,283 · Tax withholding (F): 16,073 @ $4.24 · Option exercise (M): 41,533 (derivative) @ $0 · Option exercise (M): 9,750 (derivative) @ $0 · Grant/award (A): 173,500 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Vavricka John — Chief Commercial Officer | Option exercise (M): 42,083 · Tax withholding (F): 11,570 @ $4.24 · Option exercise (M): 33,333 (derivative) @ $0 · Option exercise (M): 8,750 (derivative) @ $0 · Grant/award (A): 119,520 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Hammond Janet MJ — Chief Development Officer | Option exercise (M): 58,050 · Tax withholding (F): 14,136 @ $4.24 · Option exercise (M): 46,800 (derivative) @ $0 · Option exercise (M): 11,250 (derivative) @ $0 · Grant/award (A): 177,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Foster Wayne — EVP, Chief Accounting Officer | Option exercise (M): 41,333 · Tax withholding (F): 12,132 @ $4.24 · Option exercise (M): 33,333 (derivative) @ $0 · Option exercise (M): 8,000 (derivative) @ $0 · Grant/award (A): 108,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Corcoran Andrea — See Remarks | Option exercise (M): 54,866 · Tax withholding (F): 16,104 @ $4.24 · Option exercise (M): 44,366 (derivative) @ $0 · Option exercise (M): 10,500 (derivative) @ $0 · Grant/award (A): 180,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Sommadossi Jean-Pierre — President, CEO, and Chairman, Director | Option exercise (M): 272,983 · Tax withholding (F): 106,093 @ $4.24 · Option exercise (M): 300,000 @ $1.24 · Option exercise (M): 173,466 (derivative) @ $0 · Option exercise (M): 99,517 (derivative) @ $0 · Option exercise (M): 300,000 (derivative) @ $0 | EDGAR |
| 2025-06-24 | 4 | Adams Jerome M. — Director | Option exercise (M): 29,600 @ $0 · Grant/award (A): 29,600 (derivative) @ $0 · Grant/award (A): 41,200 (derivative) @ $0 · Option exercise (M): 29,600 (derivative) @ $0 | EDGAR |
| 2025-06-24 | 4 | Murphy Polly A. — Director | Option exercise (M): 29,600 @ $0 · Grant/award (A): 29,600 (derivative) @ $0 · Grant/award (A): 41,200 (derivative) @ $0 · Option exercise (M): 29,600 (derivative) @ $0 | EDGAR |
| 2025-06-24 | 4 | Lucidi Bruno — Director | Option exercise (M): 29,600 @ $0 · Grant/award (A): 29,600 (derivative) @ $0 · Grant/award (A): 41,200 (derivative) @ $0 · Option exercise (M): 29,600 (derivative) @ $0 | EDGAR |
| 2025-06-24 | 4 | Berman Howard — Director | Grant/award (A): 164,800 (derivative) @ $0 | EDGAR |
| 2025-06-24 | 4 | Polsky Bruce — Director | Option exercise (M): 29,600 @ $0 · Grant/award (A): 29,600 (derivative) @ $0 · Grant/award (A): 41,200 (derivative) @ $0 · Option exercise (M): 29,600 (derivative) @ $0 | EDGAR |
| 2025-06-24 | 4 | Duncan Barbara Gayle — Director | Option exercise (M): 29,600 @ $0 · Grant/award (A): 29,600 (derivative) @ $0 · Grant/award (A): 41,200 (derivative) @ $0 · Option exercise (M): 29,600 (derivative) @ $0 | EDGAR |
| 2025-06-24 | 4 | BERGER FRANKLIN M — Director | Option exercise (M): 29,600 @ $0 · Grant/award (A): 29,600 (derivative) @ $0 · Grant/award (A): 41,200 (derivative) @ $0 · Option exercise (M): 29,600 (derivative) @ $0 | EDGAR |
| 2025-02-24 | 4 | Kirsch Arthur S — Director | Grant/award (A): 164,800 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Hammond Janet MJ — Chief Development Officer | Option exercise (M): 46,800 · Grant/award (A): 11,250 · Tax withholding (F): 14,134 @ $3.06 · Option exercise (M): 46,800 (derivative) @ $0 · Grant/award (A): 11,250 (derivative) @ $0 · Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Vavricka John — Chief Commercial Officer | Option exercise (M): 33,333 · Grant/award (A): 8,750 · Tax withholding (F): 11,517 @ $3.06 · Option exercise (M): 33,333 (derivative) @ $0 · Grant/award (A): 8,750 (derivative) @ $0 · Grant/award (A): 132,800 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Horga Maria Arantxa — Chief Medical Officer | Option exercise (M): 41,533 · Grant/award (A): 9,750 · Tax withholding (F): 16,071 @ $3.06 · Option exercise (M): 41,533 (derivative) @ $0 · Grant/award (A): 9,750 (derivative) @ $0 · Grant/award (A): 192,800 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Foster Wayne — EVP, Chief Accounting Officer | Option exercise (M): 33,333 · Grant/award (A): 8,000 · Tax withholding (F): 12,062 @ $3.06 · Option exercise (M): 33,333 (derivative) @ $0 · Grant/award (A): 8,000 (derivative) @ $0 · Grant/award (A): 120,100 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Corcoran Andrea — See Remarks | Option exercise (M): 44,367 · Grant/award (A): 10,500 · Tax withholding (F): 16,102 @ $3.06 · Option exercise (M): 44,367 (derivative) @ $0 · Grant/award (A): 10,500 (derivative) @ $0 · Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Sommadossi Jean-Pierre — President, CEO, and Chairman, Director | Option exercise (M): 173,467 · Grant/award (A): 99,517 · Tax withholding (F): 88,601 @ $3.06 · Option exercise (M): 173,467 (derivative) @ $0 · Grant/award (A): 99,518 (derivative) @ $0 · Grant/award (A): 440,000 (derivative) @ $0 | EDGAR |
| 2025-01-17 | 4 | BERGER FRANKLIN M — Director | Purchase (P): 15,000 @ $3.19 · Purchase (P): 10,000 @ $3.36 | EDGAR |
| 2025-01-17 | 4/A | BERGER FRANKLIN M — Director | Purchase (P): 15,000 @ $3.19 · Purchase (P): 10,000 @ $3.36 | EDGAR |
| 2024-12-12 | 4 | BERGER FRANKLIN M — Director | Sale (S): 359,606 @ $2.85 | EDGAR |
| 2024-09-19 | 4 | Sommadossi Jean-Pierre — President, CEO, and Chairman, Director | Sale (S): 33,941 @ $4.05 · Sale (S): 22,187 @ $4.03 · Sale (S): 1,841 @ $4.00 | EDGAR |
| 2024-06-21 | 4 | Adams Jerome M. — Director | Grant/award (A): 29,600 (derivative) @ $0 · Grant/award (A): 41,200 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Lucidi Bruno — Director | Grant/award (A): 29,600 (derivative) @ $0 · Grant/award (A): 41,200 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Murphy Polly A. — Director | Grant/award (A): 29,600 (derivative) @ $0 · Grant/award (A): 41,200 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Polsky Bruce — Director | Sale (S): 17,544 @ $3.49 · Grant/award (A): 29,600 (derivative) @ $0 · Grant/award (A): 41,200 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Duncan Barbara Gayle — Director | Grant/award (A): 29,600 (derivative) @ $0 · Grant/award (A): 41,200 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | BERGER FRANKLIN M — Director | Grant/award (A): 29,600 (derivative) @ $0 · Grant/award (A): 41,200 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Murphy Polly A. — Director | Option exercise (M): 33,150 @ $0 · Option exercise (M): 33,150 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Lucidi Bruno — Director | Option exercise (M): 33,150 @ $0 · Option exercise (M): 33,150 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Adams Jerome M. — Director | Option exercise (M): 33,150 @ $0 · Option exercise (M): 33,150 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Polsky Bruce — Director | Option exercise (M): 33,150 @ $0 · Option exercise (M): 33,150 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Duncan Barbara Gayle — Director | Option exercise (M): 33,150 @ $0 · Option exercise (M): 33,150 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | BERGER FRANKLIN M — Director | Option exercise (M): 33,150 @ $0 · Option exercise (M): 33,150 (derivative) @ $0 | EDGAR |
Recent 8-K events — Atea Pharmaceuticals, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-09 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-09 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-22 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-08 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-20 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=AVIR returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs